---
schema_version: "secwatch.filing_event.v1"
accession: "0001493152-24-043915"
form_type: "8-K"
ticker: "CING"
cik: "0001862150"
company_name: "Cingulate Inc."
filed_at: "2024-11-07T23:59:59+00:00"
generated_at: "2026-05-30T03:54:02.233128+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.7
calibrated_materiality_score: 0.7
confidence: "high"
source: SEC EDGAR
---

# Cingulate posts narrower Q3 loss, cash jumps to $10M as it advances ADHD drug toward mid-2025 NDA

## Summary
- Net loss $3.2M vs $6.0M in Q3 2023; R&D expenses fell $2.5M to $1.4M.
- Cash and equivalents $10M at Sep 30, 2024, up from $52K at Dec 31, 2023.
- Working capital $9.8M, an increase of $19.5M from negative $9.6M at year-end 2023.
- Raised ~$12.5M in Q3; cash runway extended into Q3 2025.
- Commenced final FDA food-effect study for CTx-1301; data readout by end of 2024; NDA submission targeted mid-2025.

## SEC filing metadata
- accession: 0001493152-24-043915
- form_type: 8-K
- ticker: CING
- cik: 0001862150
- company_name: Cingulate Inc.
- filed_at: 2024-11-07T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.7
- calibrated_materiality_score: 0.7
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1862150/000149315224043915/0001493152-24-043915-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1862150/000149315224043915/form8-k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001493152-24-043915
- JSON: https://secwatch.observer/filing/0001493152-24-043915.json
- Plain text: https://secwatch.observer/filing/0001493152-24-043915.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.